Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma

Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Webb captures top of iconic horsehead nebula in unprecedented detail

NASA’s James Webb Space Telescope has captured the sharpest infrared images to date of a zoomed-in portion of one of the most distinctive objects in our skies, the Horsehead Nebula….

Cost-effective, high-capacity, and cyclable lithium-ion battery cathodes

Charge-recharge cycling of lithium-superrich iron oxide, a cost-effective and high-capacity cathode for new-generation lithium-ion batteries, can be greatly improved by doping with readily available mineral elements. The energy capacity and…

Novel genetic plant regeneration approach

…without the application of phytohormones. Researchers develop a novel plant regeneration approach by modulating the expression of genes that control plant cell differentiation.  For ages now, plants have been the…

Partners & Sponsors